Power Law company profile

nkf-pharma

Biotech & Life Sciences · Nanjing City, China · Founded 2000 · IPO 2017 Thoroughbred

Nanjing King-friend Biochemical Pharmaceutical is focused on research, production, and sales of raw material medicines of heparin sodium

Valuation

$2.00B

Market cap · May/2026

Revenue

$539M

Latest reported FY

EBITDA

$159M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

2 investors on nkf-pharma's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Seed 2 investors entered at this stage

Matrix Partners China

Eight Roads Ventures

Global footprint

Where nkf-pharma has talent and traffic

Workforce by country

🇨🇳 China · Nanjing City HQ

Book a demo for the full country breakdown

Web traffic by country

30 monthly visits
across markets

🇺🇸 United States0%

Top 1 markets shown

Market sentiment

What the market is saying about nkf-pharma

An AI-synthesized read of the highest-engagement posts about nkf-pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See nkf-pharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles